Posted by Michael Wonder on 05 Dec 2019
Decision to fund two new cancer treatments: olaparib and fulvestrant
5 December 2019 - PHARMAC is pleased to announce a decision to fund two new cancer treatments and amend the contractual arrangements for one currently funded treatment through an agreement with AstraZeneca.
In summary, two new treatments for cancer will be funded:
- Olaparib (Lynparza) for BRCA-mutated relapsed ovarian cancer from 1 February 2020
- Fulvestrant (Faslodex) as a second-line treatment for locally advanced or metastatic oestrogen receptor positive breast cancer as soon as practicable following Medsafe approval
